Frederick Richards
- Oncology top 2%
- Lung Cancer Research Studies 18
- Cancer Treatment and Pharmacology 17
- Hematology top 2%
- Genetics top 2%
- Chronic Lymphocytic Leukemia Research 5
- Cancer Research top 5%
-
- Lung Cancer Treatments and Mutations 19
-
- Neuroendocrine Tumor Research Advances 11
-
- Cancer therapeutics and mechanisms 10
-
- Acute Lymphoblastic Leukemia research 10
-
- Lymphoma Diagnosis and Treatment 8
- Co-authors
- Charles L. SpurrM. Robert CooperDougľas R. WhiteHyman B. MussDon V. JacksonL. Douglas CaseJohn J. StuartRobert L. Capizzi
- Cited by
- OncologyHematologyGenetics
- Journals
- Cancer (22 papers)Journal of Clinical Oncology (8 papers)Cancer Chemotherapy and Pharmacology (5 papers)
- Partner nations
- United StatesCanadaUnited Kingdom
In The Last Decade
Frederick Richards
100 papers receiving 2.3k citations
Peers
Comparison fields: 5 of 108
- Oncology 1.2k
- Hematology 446
- Genetics 372
- Cancer Research 363
- Pulmonary and Respiratory Medicine 497
Countries citing papers authored by Frederick Richards
This map shows the geographic impact of Frederick Richards's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by Frederick Richards with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites Frederick Richards more than expected).
Fields of papers citing papers by Frederick Richards
This network shows the impact of papers produced by Frederick Richards. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by Frederick Richards. The network helps show where Frederick Richards may publish in the future.
Co-authorship network
The 25 scholars most cited alongside Frederick Richards, linked wherever they have co-authored with each other. Click a name or a connecting line to browse the papers they share.
All Works
| # | Work | ||
|---|---|---|---|
| 1 | 2000 | 1 | |
| 2 | 1994 | 139 | |
| 3 | 1993 | 9 | |
| 4 | 1992 | 3 | |
| 5 | 1991 | 131 | |
| 6 | 1991 | 35 | |
| 7 | 1991 | 22 | |
| 8 | 1990 | 17 | |
| 9 | 1990 | 61 | |
| 10 | 1990 | 30 | |
| 11 | 1988 | 35 | |
| 12 | 1988 | 47 | |
| 13 | 1988 | 6 | |
| 14 | 1986 | 30 | |
| 15 | 1984 | 46 | |
| 16 | Phase II trial of anthracenedicarboxaldehyde (ADC) in advanced colorectal cancer: A CALGB study | 1982 | 1 |
| 17 | 1982 | 4 | |
| 18 | 1979 | 88 | |
| 19 | 1978 | 11 | |
| 20 | Adriamycin-methotrexate combination chemotherapy of advanced carcinoma of the cervix. | 1977 | 7 |
About Frederick Richards
Frederick Richards is a scholar working on Oncology, Genetics and Hematology, having authored 100 papers that have together received 2.5k indexed citations. Recurring topics across this work include Lung Cancer Treatments and Mutations (19 papers), Lung Cancer Research Studies (18 papers), Cancer Treatment and Pharmacology (17 papers), Neuroendocrine Tumor Research Advances (11 papers), Cancer therapeutics and mechanisms (10 papers), Acute Lymphoblastic Leukemia research (10 papers), Lymphoma Diagnosis and Treatment (8 papers) and Chronic Lymphocytic Leukemia Research (5 papers). The work is most often cited by research in Oncology (1.2k citations), Hematology (446 citations) and Genetics (372 citations). Frederick Richards has collaborated with scholars based in United States, Canada and United Kingdom. Frequent co-authors include Charles L. Spurr, M. Robert Cooper, Dougľas R. White, Hyman B. Muss, Don V. Jackson, L. Douglas Case, John J. Stuart, Robert L. Capizzi, Bayard L. Powell and David H. Buss. Their work appears in journals such as Cancer, Journal of Clinical Oncology, Cancer Chemotherapy and Pharmacology, International Journal of Radiation Oncology*Biology*Physics and Investigational New Drugs.
Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.